201 related articles for article (PubMed ID: 16620143)
21. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
Spencer TJ; Adler LA; McGough JJ; Muniz R; Jiang H; Pestreich L;
Biol Psychiatry; 2007 Jun; 61(12):1380-7. PubMed ID: 17137560
[TBL] [Abstract][Full Text] [Related]
22. Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations.
Patrick KS; Radke JL; Raymond JR; Koller L; Nguyen LV; Rodriguez W; Straughn AB
Pharmacotherapy; 2019 Jun; 39(6):677-688. PubMed ID: 30351459
[TBL] [Abstract][Full Text] [Related]
23. A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: late-day symptom control.
Brams M; Turnbow J; Pestreich L; Giblin J; Childress A; McCague K; Muniz R
J Clin Psychopharmacol; 2012 Oct; 32(5):637-44. PubMed ID: 22926597
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
Greenhill LL; Muniz R; Ball RR; Levine A; Pestreich L; Jiang H
J Am Acad Child Adolesc Psychiatry; 2006 Jul; 45(7):817-23. PubMed ID: 16832318
[TBL] [Abstract][Full Text] [Related]
25. A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder.
Wigal SB; Greenhill LL; Nordbrock E; Connor DF; Kollins SH; Adjei A; Childress A; Stehli A; Kupper RJ
J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):562-9. PubMed ID: 25470572
[TBL] [Abstract][Full Text] [Related]
26. Does chirality matter? pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder.
Quinn D
J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S62-6. PubMed ID: 18480679
[TBL] [Abstract][Full Text] [Related]
27. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
28. Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder.
Childress A; Mehrotra S; Gobburu J; McLean A; DeSousa NJ; Incledon B
J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):10-18. PubMed ID: 29039979
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
31. Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children.
Anderson VR; Scott LJ
Drugs; 2006; 66(8):1117-26. PubMed ID: 16789796
[TBL] [Abstract][Full Text] [Related]
32. Extended-release dexmethylphenidate 30 mg/d versus 20 mg/d: duration of attention, behavior, and performance benefits in children with attention-deficit/hyperactivity disorder.
Silva RR; Brams M; McCague K; Pestreich L; Muniz R
Clin Neuropharmacol; 2013; 36(4):117-21. PubMed ID: 23860345
[TBL] [Abstract][Full Text] [Related]
33. Methylphenidate (OROS formulation).
Keating GM; McClellan K; Jarvis B
CNS Drugs; 2001; 15(6):495-500; discussion 501-3. PubMed ID: 11524026
[TBL] [Abstract][Full Text] [Related]
34. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
[TBL] [Abstract][Full Text] [Related]
35. Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder.
McGough JJ; Pataki CS; Suddath R
Expert Rev Neurother; 2005 Jul; 5(4):437-41. PubMed ID: 16026226
[TBL] [Abstract][Full Text] [Related]
36. Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and D,L-methylphenidate and placebo in a laboratory classroom setting.
Silva R; Muniz R; McCague K; Childress A; Brams M; Mao A
Psychopharmacol Bull; 2008; 41(1):19-33. PubMed ID: 18362868
[TBL] [Abstract][Full Text] [Related]
37. Update on methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder.
Pheils J; Ehret MJ
Am J Health Syst Pharm; 2021 May; 78(10):840-849. PubMed ID: 33954419
[TBL] [Abstract][Full Text] [Related]
38. Open-label study of dexmethylphenidate hydrochloride in children and adolescents with attention deficit hyperactivity disorder.
Silva R; Tilker HA; Cecil JT; Kowalik S; Khetani V; Faleck H; Patin J
J Child Adolesc Psychopharmacol; 2004; 14(4):555-63. PubMed ID: 15662147
[TBL] [Abstract][Full Text] [Related]
39. Population Pharmacokinetic-Pharmacodynamic Modeling of a Novel Methylphenidate Extended-Release Orally Disintegrating Tablet in Pediatric Patients With Attention-Deficit/Hyperactivity Disorder.
Teuscher NS; Sikes CR; McMahen R; Engelking D
J Clin Psychopharmacol; 2018 Oct; 38(5):467-474. PubMed ID: 30119076
[TBL] [Abstract][Full Text] [Related]
40. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder.
Greenhill LL; Findling RL; Swanson JM;
Pediatrics; 2002 Mar; 109(3):E39. PubMed ID: 11875167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
